**Table C-8. MDCT details of comparative accuracy studies**

| **Study** | **MDCT: 4 vs. 16 vs. 64 Detector Row or Other** | **MDCT: Slice Thickness (if NR, Then Record Machine Name)** | **MDCT: Whether Reformats Used (e.g., Coronal, Sagittal) or Only Axial** | **MDCT: Contrast Y or N** | **MDCT: Type of Contrast** | **MDCT: Phases of Enhancement Dynamic vs. Routine; Arterial/Portal Venous/Equilibrium Means Dynamic** |
| --- | --- | --- | --- | --- | --- | --- |
| Fang et al. 201216 | 64 | 0.67 mm | Y | Y | 80–100 mL Iopamiro | Dual phase |
| Herrmann et al. 201217 | NR | NR | NR | NR | NR | NR |
| Tellez-Avila et al. 201218 | 16 or 64 | 3mm–5mm | Coronal reformatted images | Y | 120 mL of Conray was given 45 seconds before CT examination. 40 mL of ioditrast M60 was diluted in 1,000 mL of water an given to all patients orally 1 hour before CT imaging | Dynamic |
| Holzapfel et al. 201119 | 64 | 0.6 mm | Y | Y | 120 mL Imeron 300 | Dual-phase |
| Koelblinger et al. 201120 | 64 | 0.6 mm | Y | Y | 150 mL Iomeprol | Dynamic |
| Motosugi et al. 201121 | 16 | 5 mm | NR | Y | 300 mg/mL Omnipaque 300 | Dynamic |
| Rao et al. 201122 | 16 | 0.75 mm and 0.625 mm | Y | Y | 300mg Ultravist | Three-phase |
| Shami et al. 201123 | - | - | - | - | - | - |
| Takakura et al. 201124 | 64 | Definition, Siemens, Erlangen, Germany | Not specified | Yes | (Iopamiron 370, Bayer Schering Pharma, Berlin, Germany) | Dual (arterial and delayed presumably from 90 second delay |
| Imai et al. 201025 | 64 | 0.5 mm | NR | Y | Iopamiron 2 mL/kg | Dual-phase |
| Lee et al. 201026 | 4 | 1.25 mm | Y | Y | Iopromide 150 mL | Dual phase |
| Kauhanen et al. 200927 | 64 | 5 mm | N | Y | Iomerol 400 mg/mL 1.5mL contrast/kg | Four-phase |
| Farma et al. 200828 | NR | NR | NR | NR | NR | NR |
| Saif et al. 200829 | 4 | 1 to 3 mm | N | Yes | Gastrograffin | NR |
| Schick et al. 200830 | 16 | 0.75 mm upper abdomen | Y | Y | 140 mL Iomeprol | Dual-phase |
| Casneuf et al. 200731 | 16 | 3 mm | NR | Y | 140mL Iodixanol 320 mg iodine per mL | Venous |
| Tamm et al. 200732 | 4 | 2.5 mm first phase, 5 mm second phase | N | Y | 150mL Ioversol 350 mg Iodine/mL | Dual-phase |

|  |
| --- |
| **Table C-8. MDCT details of comparative accuracy studies (continued)** |
| **Study** | **MDCT: 4 vs. 16 vs. 64 Detector Row or Other** | **MDCT: Slice Thickness (if NR, Then Record Machine Name)** | **MDCT: Whether Reformats Used (e.g., Coronal, Sagittal) or Only Axial** | **MDCT: Contrast Y or N** | **MDCT: Type of Contrast** | **MDCT: Phases of Enhancement Dynamic vs. Routine; Arterial/Portal Venous/Equilibrium Means Dynamic** |
| Mehmet Ertuk et al. 200633 | 16 | 0.5 mm | Y | Y | 350 mg/mL Iomeron | Three-phase |
| Heinrich et al. 200534 | 4 | 5 mm | Axial | Y | Oral contrast | NR |
| Agarwal et al. 200435 | NR | 1.25 mm (parenchymal phase); 2.5 mm (portal phase) | NR | Y | 150 mL of nonionic contrast material (Optiray 320, Mallinckrodt Inc., St. Louis, MO) | Dynamic |
| DeWitt et al. 200436 | 4 | first phase 1.3 mm effective section thickness, second phase 3.2 mm effective section thickness | Sometimes (NR percentage of procedures) | Y | 150 mL Isovue-300, 300 mg Iodine/mL | Dual phase |
| Lemke et al. 200437 | NR | NR | NR | Y | 100 mL iopromide (Ultravist 370, Schering AG) | Dynamic |
| Soriano et al. 200438 | 4 | 8mm | Y | Y | Iohexol 64.75g | Dual-phase |
| Rieber et al. 200039 | NR | NR | NR | Y | 150 mL iopromide (Ultravist 300, Schering, Berlin) | Dynamic |